Alzheimer's disease

One of the most-watched Alzheimer's therapies in the clinic, Biogen Inc (NASDAQ: BIIB)-Eisai Limited's (OTC: ESALY) experimental lecanemab reduced clinical decline on the scale by 27% compared to the placebo at 18 months in early Alzheimer's. In July 2022, the FDA...

Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate. What Happened:  Biogen and Eisai said the global Phase 3 confirmatory study, "Clarity...

Cognition Therapeutics Inc (NASDAQ: CGTX) presented a proteomic analysis of clinical biomarker data from the SPARC study of CT1812 in mild-to-moderate Alzheimer's disease at the Alzheimer's Association International Conference.  What Happened: The results support the proposed...

AbbVie Inc (NYSE: ABBV) has decided to terminate the CD33 collaboration program with Alector Inc (NASDAQ: ALEC), developing AL003 for Alzheimer’s disease as one of two programs under the co-development and option agreement. As previously disclosed, Alector was ...

The commercial failure of Biogen Inc's (NASDAQ: BIIB) drug Aduhelm has put a new focus on the research into the causes of Alzheimer's disease. Aduhelm was expected as a potential blockbuster that targeted a root cause of the disease by clearing a protein known as amyloid from the...

Eisai Co Ltd (OTC: ESALY) has completed the rolling submission of the FDA marketing application under the accelerated approval for lecanemab (BAN2401) for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD. Eisai is collaborating with Biogen Inc...

Cassava Sciences Inc (NASDAQ: SAVA) shares are shedding over 20% after The New York Times detailed new allegations related to the studies of the company's experimental Alzheimer's therapy, simufilam. Among the latest concerns highlighted in the NYT article include a report...

Longeveron Inc (NASDAQ: LGVN) has announced a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) to add Miami VA clinical site to its ongoing Phase 2 Alzheimer’s Disease (AD) trial.  Why It Matters: This marks the...

Centers for Medicare and Medicaid Services (CMS) finalized its decision to restrict coverage for Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug Aduhelm and other amyloid-targeted drugs to just patients participating in clinical trials. "Monoclonal antibodies...

Longeveron Inc (NASDAQ: LGVN) announced the publication of Phase 1 trial results of Lomecel-B on patients with mild Alzheimer's disease (AD) in the Alzheimer's & Dementia journal. The 33-subject trial met its primary endpoint, demonstrating that Lomecel-B was well...

In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have released more data on lecanemab, another anti-Alzheimer's drug.  The lecanemab's Phase 2b study data were presented at the annual AD/PD meeting. The ratio...

Biogen Inc (NASDAQ: BIIB) has announced new data from the long-term extension phase of the Phase 3 trials of Aduhelm (aducanumab-avwa) in Alzheimer's disease. The data exhibited that after nearly two and a half years of treatment (128 weeks) with Aduhelm, patients continued to...

Prothena Corporation plc (NASDAQ: PRTA) presented new preclinical data from its dual Aβ/tau and tandem C-terminal α-synuclein vaccine programs in Alzheimer's disease (AD) and Parkinson's disease (PD), respectively.  The data were presented at the...

Gain Therapeutics Inc (NASDAQ: GANX) has presented new preclinical data from its Parkinson's and Alzheimer's Disease programs.  These results were highlighted at the International Conference on Alzheimer's (AD) and Parkinson's Diseases (PD).  The data shows...

Eisai Co Ltd (OTC: ESALY) is giving up its right to share in profits from Aduhelm (aducanumab-avwa), which was developed in partnership with Biogen Inc (NASDAQ: BIIB). Biogen and Eisai have amended their agreement to give Biogen full authority to make regulatory and sales...